Vendor qualification criteria pain management practices use
Pain management and physical medicine groups typically fold a biologics supplier into their existing vendor review for injectable and biologic products: documentation on file, licensure verification, and terms that match how the practice reorders. A practice weighing Wharton's jelly against exosome products will usually want to understand the regulatory distinction between the two product families before deciding which, if either, fits its supply chain.
Because exosome products are generally regulated as biologic drugs and none carry FDA approval, many practices treat that product family as requiring a more involved internal review than a Wharton's jelly allograft offered under the supplier's HCT/P framework.
Augusta
NPPES registry listings, primary taxonomy, retrieved 2026-10-27
71- Pain Medicine
- 50
- Physical Medicine & Rehabilitation
- 21
Documentation a practice can request
Qualified accounts can request the certificate of analysis for a specific lot, the donor eligibility and screening summary, and a description of processing and third-party sterility testing. For exosome products, supplier-reported characterization data is available on request as well.
- Certificate of analysis by lot
- Donor eligibility summary
- Processing and sterility testing description
- Registration and licensure documentation
Setting up a verified account
Account setup begins with the practice's NPI number, which Precision Biologics verifies before enabling orders. A multi-provider pain management group can list each credentialed physician under one account, keeping ordering limited to NPI-verified providers while simplifying reorders for the practice's billing or office staff.
Receiving shipments and confirming lot records
Cryopreserved products arrive overnight on dry ice in validated shipping containers, and lyophilized products ship at ambient temperature without cold-chain handling. A practice in Augusta should have staff ready to receive and log a cryopreserved shipment promptly, matching the lot number on arrival against the certificate of analysis on file.
Practices should also confirm their own standing with the Georgia medical board and counsel before treating a new product family as part of their regular supply chain; these products are not FDA approved or licensed for any disease or condition.
FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.
These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.
Frequently asked questions
Can a pain management practice in Augusta open a Precision Biologics account?+
Yes, once the practice or group NPI is verified and the ordering provider is identified.
Does the 71-provider figure mean 71 practices are buying biologics in Augusta?+
No. It is a count of 71 individual NPI-1 records with Pain Medicine or Physical Medicine & Rehabilitation as a primary taxonomy and an Augusta location, retrieved 2026-10-27, with no bearing on current purchasing.
What distinguishes Wharton's jelly products from exosome products for procurement purposes?+
Wharton's jelly products are offered under the supplier's HCT/P framework, while exosome products are generally regulated as biologic drugs with no FDA-approved products in the category; each carries different documentation and review considerations.